Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.